Quest Diagnostics Incorporated (DGX)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $28.56B
Last updated: Nov 17, 2026 at 11:03 AM ET
Quest Diagnostics Incorporated (DGX) Stock Forecast
Analysts expect Quest Diagnostics (DGX) to earn $11.32 per share in the fiscal year ending Dec 31, 2026, on revenue of $12.08B. Of 17 analysts, 9 rate the stock Buy or Strong Buy, 8 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 14 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 17 ratings average 2.35, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 53% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 11.8% |
| Buy | 7 | 41.2% |
| Hold | 8 | 47.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 17
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 5.8% and revenue estimates rise 4.5%.
- Fiscal year ending Dec 31, 2026
- $11.32
- EPS consensus, revenue $12.08B
- Fiscal year ending Dec 31, 2027
- $11.98
- EPS consensus, revenue $12.62B
- Next report
- Feb 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $11.32 | $11.25 to $11.43 | 16 | $12.08B | $12.06B to $12.10B | 15 |
| Dec 31, 2027 | $11.98 | $11.63 to $12.67 | 16 | $12.62B | $12.49B to $12.86B | 15 |
Quarterly Estimates
The EPS consensus falls from $2.71 for the quarter ending Dec 31, 2026 to $2.70 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.71 | $2.56 to $2.88 | 17 | $3.07B | $2.90B to $3.22B | 16 |
| Mar 31, 2027 | $2.70 | $2.59 to $2.84 | 10 | $3.03B | $3.00B to $3.08B | 7 |
Estimate Revisions
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 14 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1.2% from $11.19.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $11.32 | $11.32 | $11.20 | $11.19 | $11.19 | +1.1% |
| Fiscal year ending Dec 31, 2027 | $11.98 | $11.98 | $12.03 | $12.06 | $12.06 | -0.6% |
| Quarter ending Mar 31, 2027 | $2.70 | $2.76 | $2.77 | $2.77 | $2.76 | -2.4% |
Frequently Asked Questions About DGX
What is the DGX stock forecast?
Consensus analyst estimates put Quest Diagnostics's EPS at $11.32 for the fiscal year ending Dec 31, 2026, on revenue of $12.08B. The consensus rating from 17 analysts is Buy.
How do analysts rate DGX stock?
Of 17 analysts covering Quest Diagnostics, 2 rate it Strong Buy, 7 Buy, 8 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from DGX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $11.32, with estimates from $11.25 to $11.43 from 16 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $11.98, with estimates from $11.63 to $12.67 from 16 analysts.
What revenue do analysts expect from Quest Diagnostics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $12.08B, with estimates from $12.06B to $12.10B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $12.62B, with estimates from $12.49B to $12.86B.
How many analysts cover DGX?
17 analysts rate Quest Diagnostics stock, and 16 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
DGX pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts